Literature DB >> 6352281

Ciclazindol: an oral agent with weight reducing properties and hypoglycaemic activity.

M E Lean, L J Borthwick.   

Abstract

In a single blind crossover study, ciclazindol, 10-(m-chlorophenyl)-2, 3, 4, 10-tetrahydropyrimide (1, 2 alpha) indol-10-ol hydrochloride (Fig. 1), has been found to have hypoglycaemic action, and to produce reduction in appetite and weight. The mode of action appears to be different from either biguanides or sulphonylureas. Side-effects were few and mild. Metformin 500 mg b.d. had comparable hypoglycaemic effect but did not suppress appetite. Ciclazindol may be useful as a mild oral hypoglycaemic agent for obese patients, and would be suitable for once daily administration.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6352281     DOI: 10.1007/bf00544012

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  7 in total

1.  Ciclazindol and mazindol on glucose uptake into human isolated skeletal muscle: no interaction of mazindol with methysergide.

Authors:  M J Kirby; P Turner
Journal:  Br J Clin Pharmacol       Date:  1977-08       Impact factor: 4.335

2.  Some clinical pharmacological studies with ciclazindol hydrochloride [proceedings].

Authors:  R S Ehsanullah; M J Kirby; M Leighton; V M Oh
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

3.  Hyperinsulinemia secondary to chronic administration of mazindol and d-amphetamine.

Authors:  C Sirtori; A Hurwitz; D L Azarnoff
Journal:  Am J Med Sci       Date:  1971-06       Impact factor: 2.378

4.  Antidepressant activity and pharmacological interactions of ciclazindol.

Authors:  K Ghose; V A Rama Rao; J Bailey; A Coppen
Journal:  Psychopharmacology (Berl)       Date:  1978-04-14       Impact factor: 4.530

5.  Sympathetic mechanisms in diet-induced thermogenesis: modification by ciclazindol and anorectic drugs.

Authors:  N J Rothwell; M J Stock; M G Wyllie
Journal:  Br J Pharmacol       Date:  1981-11       Impact factor: 8.739

6.  The pharmacokinetics of ciclazindol (Wy 23409) in human volunteers.

Authors:  A J Swaisland; R A Franklin; P J Southgate; A J Coleman
Journal:  Br J Clin Pharmacol       Date:  1977-02       Impact factor: 4.335

7.  Cardiovascular and autonomic actions of ciclazindol and tricyclic antidepressants.

Authors:  J F Waterfall; M A Smith; W H Gaston; J Maher; G Warburton
Journal:  Arch Int Pharmacodyn Ther       Date:  1979-07
  7 in total
  3 in total

1.  Telescoped synthesis of C3-functionalized (E)-arylamidines using Ugi-Mumm and regiospecific quinazolinone rearrangements.

Authors:  Victor A Jaffett; Alok Nerurkar; Xufeng Cao; Ilia A Guzei; Jennifer E Golden
Journal:  Org Biomol Chem       Date:  2019-03-20       Impact factor: 3.876

Review 2.  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Authors:  Shelley R Salpeter; Elizabeth Greyber; Gary A Pasternak; Edwin E Salpeter
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

3.  Comparison of the effects of chronic administration of ciclazindol and desipramine on pupillary responses to tyramine, methoxamine and pilocarpine in healthy volunteers.

Authors:  F A Kerr; E Szabadi
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.